| Medical and Health Sciences | Lifetime | 97 | US 53 | 100.00 |
| Medical and Health Sciences | 2021-2025 | 270 | US 96 | 99.95 |
| Cardiology and Cardiovascular Medicine | Lifetime | 19 | US 16 | 99.98 |
| Surgery | Lifetime | 79 | US 43 | 99.93 |
| Radiology, Nuclear Medicine and Imaging | Lifetime | 222 | US 128 | 99.44 |
| Internal Medicine | Lifetime | 98 | US 34 | 97.80 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 646 | US 341 | 97.88 |
| Surgery | 2021-2025 | 45 | US 18 | 99.74 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 92 | US 48 | 99.60 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 169 | US 77 | 97.08 |
| Radiology, Nuclear Medicine and Imaging | 2021-2025 | 509 | US 185 | 89.44 |
| Nutrition and Dietetics | 2021-2025 | 317 | US 66 | 86.90 |
| Acute Myocardial Infarction Research | Lifetime | 5 | US 4 | 99.98 |
| Antiplatelet Therapy and Cardiovascular Diseases | Lifetime | 4 | US 3 | 99.98 |
| Cardiac Imaging and Diagnostics | Lifetime | 30 | US 19 | 99.93 |
| Coronary Interventions and Diagnostics | Lifetime | 16 | US 10 | 99.94 |
| Atrial Fibrillation Management and Outcomes | Lifetime | 36 | US 17 | 99.87 |
| Venous Thromboembolism Diagnosis and Management | Lifetime | 31 | US 13 | 99.83 |
| Lipoproteins and Cardiovascular Health | Lifetime | 35 | US 21 | 99.79 |
| Peripheral Artery Disease Management | Lifetime | 36 | US 27 | 99.56 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 136 | US 68 | 99.52 |
| Heart rate and cardiovascular health | Lifetime | 4 | US 1 | 99.42 |
| Heart Failure Treatment and Management | Lifetime | 91 | US 54 | 99.65 |
| Cerebrovascular and Carotid Artery Diseases | Lifetime | 187 | US 86 | 99.40 |
| Blood Pressure and Hypertension Studies | Lifetime | 166 | US 73 | 99.41 |
| Diabetes Treatment and Management | Lifetime | 189 | US 85 | 99.23 |
| Cardiac Health and Mental Health | Lifetime | 163 | US 100 | 98.54 |
| Cardiovascular Function and Risk Factors | Lifetime | 583 | US 310 | 98.97 |
| Cardiac, Anesthesia and Surgical Outcomes | Lifetime | 786 | US 393 | 98.48 |
| Acute Ischemic Stroke Management | Lifetime | 595 | US 233 | 98.36 |
| Cardiac electrophysiology and arrhythmias | Lifetime | 824 | US 407 | 98.14 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 696 | US 289 | 97.77 |
| Cardiovascular Disease and Adiposity | Lifetime | 742 | US 353 | 96.53 |
| Cardiovascular Health and Disease Prevention | Lifetime | 916 | US 340 | 96.29 |
| Cardiovascular Issues in Pregnancy | Lifetime | 544 | US 228 | 96.08 |
| Heparin-Induced Thrombocytopenia and Thrombosis | Lifetime | 310 | US 122 | 94.36 |
| Pharmaceutical Economics and Policy | Lifetime | 715 | US 312 | 92.97 |
| Hyperglycemia and glycemic control in critically ill and hospitalized patients | Lifetime | 903 | US 387 | 91.22 |
| GDF15 and Related Biomarkers | Lifetime | 687 | US 214 | 78.33 |
| Aortic Thrombus and Embolism | Lifetime | 499 | US 188 | 73.77 |
| Antiplatelet Therapy and Cardiovascular Diseases | 2021-2025 | 7 | US 4 | 99.72 |
| Acute Myocardial Infarction Research | 2021-2025 | 39 | US 14 | 99.21 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 35 | US 15 | 99.28 |
| Fatty Acid Research and Health | 2021-2025 | 18 | US 7 | 97.23 |
| Cardiac Imaging and Diagnostics | 2021-2025 | 146 | US 51 | 98.75 |
| Coronary Interventions and Diagnostics | 2021-2025 | 78 | US 23 | 98.84 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 67 | US 24 | 97.77 |
| Atrial Fibrillation Management and Outcomes | 2021-2025 | 183 | US 54 | 98.53 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 323 | US 109 | 96.89 |
| Venous Thromboembolism Diagnosis and Management | 2021-2025 | 306 | US 96 | 96.64 |
| Diabetes Treatment and Management | 2021-2025 | 297 | US 102 | 96.70 |
| Heart Failure Treatment and Management | 2021-2025 | 396 | US 138 | 95.21 |
| Cardiovascular Disease and Adiposity | 2021-2025 | 430 | US 112 | 88.47 |
| Erythropoietin and Anemia Treatment | 2021-2025 | 132 | US 45 | 87.60 |
| Eicosanoids and Hypertension Pharmacology | 2021-2025 | 150 | US 61 | 83.68 |
| Hyperglycemia and glycemic control in critically ill and hospitalized patients | 2021-2025 | 221 | US 95 | 83.81 |
| Blood transfusion and management | 2021-2025 | 230 | US 103 | 83.70 |
| Peripheral Artery Disease Management | 2021-2025 | 831 | US 339 | 84.11 |
| Lipid metabolism and disorders | 2021-2025 | 393 | US 95 | 74.59 |
| Pharmaceutical Economics and Policy | 2021-2025 | 743 | US 244 | 74.41 |
| Apelin-related biomedical research | 2021-2025 | 890 | US 137 | 22.67 |
